AstraZeneca Q1 net profit down, core EPS upStaff Writer | April 27, 2017
AstraZeneca reported that its first-quarter profit before tax declined to $582 million from last year's $723 million last year.
AstraZeneca Core earnings per share increased 4% to $0.99
Core earnings per share increased 4% to $0.99.
Total revenue declined 12 percent to $5.41 billion from last year's $6.12 billion. At constant rates, revenues fell 10 percent.
The Product Sales declined as performance mainly reflected the residual impact of the US Crestor patent expiry.
Further, the company confirmed its financial guidance for 2017. The company continues to expect total revenue to decline a low to mid single-digit percentage and core earnings per share to decline a low to mid teens percentage for the full year. ■